BTSG
BrightSpring Health Services, Inc. Common Stock
BTSG has the edge over OSCR overall, supported by lower modeled downside and stronger valuation.
OSCR
Oscar Health, Inc.
OSCR offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
BTSG Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Stable |
BTSG's revenue, profitability and cash flow are currently healthy, and its balance sheet is stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
BTSG PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 30x | $71.45 | — |
| Cheap | 38x | $69.24 | -3.1% |
| Current | 39x | $71.45 | — |
| Fair | 53x | $98.23 | +37% |
| Expensive | 72x | $132 | +84% |
Historical ranges are pointers, not guarantees.
BTSG's PE is in its cheap range at 39x. If earnings grow as analysts expect, today's price would be 30x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over BTSG in the historical PE scenario, which offers more potential upside but is not a forecast.
BTSG Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for BTSG, with profitability improving. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
BTSG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.37 | +29% |
| Q3 2026 | $1.84 | +188% |
| Q2 2026 | $1.65 | +385% |
| Q1 2026 | $1.40 | +352% |
| Q4 2025 | $0.87 | +$0.96 |
| Q3 2025 | $0.64 | +$0.88 |
| Q2 2025 | $0.34 | +$1.30 |
| Q1 2025 | $0.31 | +$1.34 |
| Q4 2024 | -$0.09 | +$0.80 |
BTSG has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
BTSG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4.2B | +26% |
| Q2 2026 | $3.9B | +23% |
| Q1 2026 | $3.6B | +26% |
| Q4 2025 | $3.6B | +16% |
| Q3 2025 | $3.3B | +15% |
| Q2 2025 | $3.1B | +15% |
| Q1 2025 | $2.9B | +12% |
| Q4 2024 | $3.1B | +29% |
BTSG's revenue has grown year over year every quarter since late 2020: $4.2B last quarter, up 26% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.8% | +1.2 points |
| Q2 2026 | 3.4% | +1.8 points |
| Q1 2026 | 3.4% | +1.6 points |
| Q4 2025 | 3% | +0.5 points |
| Q3 2025 | 2.6% | +0.7 points |
| Q2 2025 | 1.5% | -0.8 points |
| Q1 2025 | 1.8% | +1.4 points |
| Q4 2024 | 2.6% | -0.3 points |
BTSG has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over BTSG on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
BTSG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $182.2M | +98% |
| Q2 2026 | $14.9M | -40% |
| Q1 2026 | $101.4M | +21% |
| Q4 2025 | $193.9M | +157% |
| Q3 2025 | $92.2M | +1180% |
| Q2 2025 | $24.7M | +$63.6M |
| Q1 2025 | $84M | +$184.6M |
| Q4 2024 | $75.3M | -48% |
BTSG generated $492M in free cash flow over the past year, up 78% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
BTSG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -50K shares |
| 1 year | +1% | +2.2M shares |
| 3 years | +29% | +49M shares |
| 5 years | +29% | +49M shares |
| Available history | +53% | +76.1M shares |
BTSG has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $60M |
| Q1 2026 | $60M |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | $325,000 |
| Q1 2024 | $325,000 |
| Q4 2023 | $325,000 |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
BTSG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.2x | Moderate |
| Q2 2026 | 2.7x | Moderate |
| Q1 2026 | 3.1x | Elevated |
| Q4 2025 | 5.3x | High |
| Q3 2025 | 5.3x | High |
| Q2 2025 | 5.8x | High |
| Q1 2025 | 5.6x | High |
| Q4 2024 | 6.2x | High |
BTSG's net debt is about 2.2 years of its operating earnings (EBITDA), down from 5.3 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over BTSG on leverage, with a lower net debt burden relative to earnings.
BTSG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 66.6 | Neutral |
| Stochastic | 76.0 | Neutral |
BTSG's weekly RSI is 67 (neutral) and its Stochastic is 76 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
BTSG PE vs Healthcare Sector
| Metric | BTSG | Sector median | Relative |
|---|---|---|---|
| PE | 39x | 26x | 50% above |
| PE % | 20 | 45 | 25 pts below |
BTSG is trading at 39x earnings, a 50% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over BTSG on valuation relative to its sector.
BTSG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $63.4 | 13% above |
| 20 week MA | $63.5 | 13% above |
| 50 week MA | $53.2 | 34% above |
| 100 week MA | $38.1 | 87% above |
OSCR has stronger trend alignment. BTSG is above 4 of 4 weekly averages versus OSCR above 5 of 5.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
BTSG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $11.0 | $17.0 | +55% |
| 2025 | $17.0 | $37.8 | +122% |
| 2026 YTD | $37.8 | $71.5 | +89% |
BTSG has finished every year since 2024 higher, and it's up 89% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over BTSG on returns for 2026, with the stronger performance.